Introduction to sunitinib (Sutent) imported original drug manufacturers and drug production background

Sunitinib (Sunitinib, trade name: Sutent) is a multi-target tyrosine kinase inhibitor developed and produced by Pfizer (Pfizer) in the United States. As a world-renowned multinational pharmaceutical company, Pfizer has profound research and development experience in the field of oncology, and sunitinib is one of the important results of its innovative research and development. The drug was initially approved by the FDA in 2006 for the treatment of advanced renal cell carcinoma and gastrointestinal stromal tumors (GIST). The indications were gradually expanded globally and included in standard treatment regimens in many countries.

Pfizer, as the world's leading pharmaceutical company, has production bases in many places around the world. The production of sunitinib's original drug strictly follows international drug production quality management standards (GMP). From raw material selection, drug synthesis to final preparation testing and packaging, every step undergoes strict quality control and regulatory review. This rigorous production system ensures the consistency of the efficacy, safety and drug stability of the original sunitinib drug, and also provides a solid guarantee for its wide recognition by medical institutions and patients in the global market.

As an important anti-tumor drug of Pfizer, sunitinib has been launched in more than 70 countries and regions around the world and is widely used in clinical practice. In China, sunitinib has been successfully approved for marketing and has been included in the scope of medical insurance reimbursement, reducing the financial burden on patients. The price of the domestically imported sunitinib original drug is about more than 4,000 yuan, and the patient's out-of-pocket payment ratio is significantly reduced after medical insurance reimbursement. In comparison, in foreign markets, in addition to original drugs, there are also lower-priced generic drug options, such as the Indian version, which costs only a few hundred yuan and is basically the same in terms of ingredients and efficacy.

As an important representative of targeted drugs, sunitinib's research and development background reflects the global pharmaceutical industry's exploration of personalized treatment and precision medicine. Leveraging Pfizer's R&D capabilities and global production and supply system, sunitinib has not only demonstrated good efficacy and safety in clinical treatment, but has also become an important drug for the treatment of international and domestic patients over the years. With the inclusion of original drugs in domestic medical insurance, patients' medication accessibility has been greatly improved, while the existence of overseas generic drugs has further broadened patients' choice channels and provided diversified medication options for patients with different economic conditions.

Reference materials:https://www.drugs.com/